US Stock MarketDetailed Quotes
ZURA Zura Bio
- 2.730
- -0.200-6.83%
Close Nov 22 16:00 ET
178.25MMarket Cap-4180P/E (TTM)
2.965High2.705Low523.12KVolume2.950Open2.930Pre Close1.46MTurnover1.41%Turnover RatioLossP/E (Static)65.29MShares6.35052wk High1.16P/B101.27MFloat Cap2.00052wk Low--Dividend TTM37.10MShs Float37.550Historical High--Div YieldTTM8.87%Amplitude2.000Historical Low2.795Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Zura Bio Stock Forum
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
NEWS
Zura Bio Raises $112.5M Through Private Placement Deal
NEWS
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
No comment yet